Literature DB >> 7857713

Constitutive secretion of bioactive transforming growth factor beta 1 by small cell lung cancer cell lines.

J R Fischer1, H Darjes, H Lahm, M Schindel, P Drings, P H Krammer.   

Abstract

We investigated effects of soluble mediators secreted by small cell lung cancer (SCLC) cell lines on modulation of cytokine-induced growth of lymphocytes. We found that interleukin-2 (IL-2)-mediated T-cell growth was inhibited by a cytokine constitutively secreted by the SCLC cell line, NCI-N417. Of several cytokines tested, only transforming growth factor beta 1 (TGF beta 1) severely suppressed IL-2-dependent T-cell growth. Using a specific anti-TGF beta 1 antibody, we found that this antibody blocked the immunosuppressive activity secreted by NCI-N417. Thus, the NCI-N417-derived immunosuppressive molecule was serologically identified as TGF beta 1. Further experiments showed that TGF beta 1 was secreted by four of eight SCLC lines tested. mRNA for TGF beta 1 was expressed in NCI-N417 and in SCLC-22H. Constitutive secretion of biologically active TGF beta 1 by SCLC lines suggests that tumour-derived immunosuppression may have clinical relevance.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7857713     DOI: 10.1016/0959-8049(94)00364-b

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  17 in total

Review 1.  Lung cancer vaccines.

Authors:  Ronan J Kelly; Giuseppe Giaccone
Journal:  Cancer J       Date:  2011 Sep-Oct       Impact factor: 3.360

Review 2.  Reversal of tumor-induced immunosuppression by TGF-beta inhibitors.

Authors:  Slawomir Wojtowicz-Praga
Journal:  Invest New Drugs       Date:  2003-02       Impact factor: 3.850

Review 3.  Tumor associated regulatory dendritic cells.

Authors:  Yang Ma; Galina V Shurin; Dmitriy W Gutkin; Michael R Shurin
Journal:  Semin Cancer Biol       Date:  2012-03-06       Impact factor: 15.707

Review 4.  Mechanisms of immune response regulation in lung cancer.

Authors:  Joanna Domagala-Kulawik; Iwona Osinska; Grazyna Hoser
Journal:  Transl Lung Cancer Res       Date:  2014-02

Review 5.  Transforming growth factor-β: A therapeutic target for cancer.

Authors:  Sulsal Haque; John C Morris
Journal:  Hum Vaccin Immunother       Date:  2017-06-02       Impact factor: 3.452

Review 6.  Targeting the immune system in non-small-cell lung cancer: bridging the gap between promising concept and therapeutic reality.

Authors:  Ronan J Kelly; James L Gulley; Giuseppe Giaccone
Journal:  Clin Lung Cancer       Date:  2010-07-01       Impact factor: 4.785

7.  Transforming growth factor beta can be a parameter of aggressiveness of pT1 colorectal cancer.

Authors:  Katarzyna Guzinska-Ustymowicz; Andrzej Kemona
Journal:  World J Gastroenterol       Date:  2005-02-28       Impact factor: 5.742

Review 8.  Bioinformatic approaches to augment study of epithelial-to-mesenchymal transition in lung cancer.

Authors:  Tim N Beck; Adaeze J Chikwem; Nehal R Solanki; Erica A Golemis
Journal:  Physiol Genomics       Date:  2014-08-05       Impact factor: 3.107

9.  Immature myeloid cells and tolerogenic cytokine profile in lung adenocarcinoma metastatic lymph nodes assessed by endobronchial ultrasound.

Authors:  Antonio Bugalho; Catarina Martins; Zelia Silva; Gloria Nunes; Andreia S Mendes; Inês Ferreira; Paula A Videira
Journal:  Tumour Biol       Date:  2015-08-12

10.  The role of Foxp3 and Tbet co-expressing Treg cells in lung carcinoma.

Authors:  Katerina Kachler; Corinna Holzinger; Denis I Trufa; Horia Sirbu; Susetta Finotto
Journal:  Oncoimmunology       Date:  2018-04-25       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.